Mycophenolate Mofetil: What Dermatologists Need To Know
Comprehensive guide to mycophenolate mofetil use in dermatology, including indications, dosing, side effects, and monitoring.
Mycophenolate mofetil (MMF), also known as mycophenolic acid (MPA), is a selective, reversible, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), primarily targeting type II isoform in T- and B-lymphocytes. Initially approved for preventing organ transplant rejection, MMF has gained prominence in dermatology for treating refractory inflammatory, autoimmune, and neoplastic skin conditions due to its lymphocyte-specific immunosuppression and favorable safety profile compared to alternatives like methotrexate, azathioprine, or cyclosporine.
What is mycophenolate mofetil?
Mycophenolate mofetil is a prodrug rapidly hydrolyzed to its active metabolite, mycophenolic acid (MPA), which selectively inhibits de novo purine synthesis in lymphocytes. Unlike myeloid cells that utilize salvage pathways, lymphocytes rely heavily on this pathway, making MMF highly specific for immune suppression with reduced toxicity to other cell types. This mechanism impairs DNA, RNA, and protein synthesis, effectively curbing lymphocyte proliferation.
Approved by the FDA in 1995 for renal, cardiac, and hepatic transplant prophylaxis, MMF (brand names CellCept, Myfortic) is used off-label in dermatology. Its appeal lies in low hepatotoxicity, nephrotoxicity, and carcinogenicity risks, positioning it as a steroid-sparing agent.
History
Mycophenolic acid was first isolated in 1893 from Penicillium brevicompactum by Italian scientist Bartolomeo Gosio. Early studies in the 1970s demonstrated its efficacy in psoriasis, but gastrointestinal intolerance limited use. The development of the prodrug MMF in the 1990s improved bioavailability and tolerability, leading to widespread transplant adoption. Dermatologic applications emerged in the early 2000s, with case series reporting success in psoriasis, atopic dermatitis, and immunobullous diseases.
Pharmacology
Mechanism of action
MMF noncompetitively inhibits IMPDH, blocking inosine monophosphate conversion to xanthine monophosphate in guanosine nucleotide synthesis. This depletes guanosine triphosphate (GTP), halting lymphocyte proliferation. It also reduces glycosylation of adhesion molecules, further dampening immune responses.
Pharmacokinetics
- Absorption: Rapidly converted to MPA; peak plasma levels in 1-2 hours (immediate-release) or 2-3 hours (enteric-coated).
- Distribution: 94% protein-bound; penetrates skin effectively.
- Metabolism: Hepatic glucuronidation to inactive MPAG; enterohepatic recirculation increases exposure.
- Elimination: Renal (MPAG excretion); half-life 16-18 hours.
- Dose adjustment: Required in renal/hepatic impairment.
Dose and administration
In dermatology, MMF dosing typically starts at 1 g twice daily (2 g/day total), titrated to 3 g/day based on response and tolerance. Enteric-coated formulations (Myfortic) reduce GI upset at equivalent doses (1.44 g twice daily = 2 g MMF).
| Condition | Typical Dose | Duration |
|---|---|---|
| Psoriasis | 2-3 g/day | 12-24 weeks |
| Atopic dermatitis | 2 g/day | 12 weeks |
| Immunobullous diseases | 2-3 g/day | Induction 4-6 months |
| Connective tissue diseases | 2 g/day | Maintenance |
Administer with food to minimize GI effects. Therapeutic drug monitoring (MPA area-under-curve) is recommended in transplants but less routine in dermatology.
Indications in dermatology
MMF is reserved for moderate-to-severe, refractory cases unresponsive to topicals, phototherapy, or first-line systemics. Key indications include:
- Psoriasis: Stable plaque psoriasis shows 40-70% PASI reduction at 2-3 g/day within 3-12 weeks.
- Atopic dermatitis: Severe refractory AD improves 68-74% on SCORAD at 2 g/day over 12-20 weeks.
- Immunobullous disorders: Pemphigus vulgaris, bullous pemphigoid respond rapidly, often steroid-sparing.
- Connective tissue diseases: Lupus (cutaneous/discoid), dermatomyositis, scleroderma.
- Other: Pyoderma gangrenosum, lichen planus, graft-versus-host disease, sarcoidosis, cutaneous Crohn’s, vasculitis.
Drug interactions
MMF interacts with drugs affecting glucuronidation or enterohepatic cycling:
- Antacids, cholestyramine: Reduce absorption.
- Azathioprine, allopurinol: Increased myelosuppression; avoid co-administration.
- Live vaccines: Contraindicated.
- Probenecid: Increases MPA levels.
- Antibiotics (e.g., norfloxacin): Disrupt gut flora, reducing recirculation.
Pregnancy and breastfeeding
MMF is contraindicated in pregnancy (FDA Pregnancy Category D; causes congenital malformations in 25-30% of exposures). Use two forms of contraception; effective contraception required 6 weeks pre-treatment, during, and 6 weeks post. Male patients: condom use recommended.
Breastfeeding: Contraindicated; MPA detected in breast milk.
Monitoring
Baseline and regular monitoring essential:
- Bloods: CBC (weekly first month, then monthly), LFTs, renal function, electrolytes.
- Infections: Screen for varicella, HBV, HCV, TB pre-treatment; PCP prophylaxis if <4 mg/kg/day prednisone equivalent.
- Cancer screening: Skin exams, Pap smears, consider colonoscopy.
| Parameter | Frequency |
|---|---|
| FBC, U&E, LFT | Weekly x1 month, 2-weekly x2, monthly |
| CMV PCR (if at risk) | Monthly initially |
Side effects
GI effects predominate (30-50%): nausea, diarrhea, abdominal pain. Others: headache, fatigue, myelosuppression (10-20%), infections (15%). Rare: progressive multifocal leukoencephalopathy, lymphoma.
- Common (>10%): Nausea, diarrhea, leukopenia.
- Serious (<1%): GI perforation, hypersensitivity pneumonitis.
Treatment cessation
Taper gradually over weeks to months to avoid rebound. No specific withdrawal syndrome, but monitor for disease flare.
Alternative names / spellings
- CellCept®
- Myfortic®
- Mycophenolic acid
- MPA
Frequently asked questions
Is mycophenolate mofetil safe for long-term use in skin diseases?
Long-term data from transplant patients (>10 years) show good tolerability, but dermatology lacks RCTs. Monitor closely for infections and malignancies.
Can MMF be used in children?
Limited pediatric data; used off-label for severe AD/pemphigus at weight-based doses (600-1200 mg/m²/day). Safety similar to adults.
How quickly does MMF work for psoriasis?
PASI improvements seen in 3 weeks; maximal at 12 weeks.
What if I get diarrhea on MMF?
Switch to enteric-coated Myfortic, take with food, or dose-split. Dose reduction if persistent.
Does MMF increase skin cancer risk?
Lower than azathioprine; UV protection essential.
References
- The Emergence of Mycophenolate Mofetil in Dermatology — J Drugs Dermatol (PMC). 2011-02-01. https://pmc.ncbi.nlm.nih.gov/articles/PMC3030212/
- Mycophenolate mofetil in dermatology — J Am Acad Dermatol (PubMed). 2009-01. https://pubmed.ncbi.nlm.nih.gov/19150270/
- Mycophenolate Mofetil: A Dermatologic Perspective — Skin Therapy Letter. 2008. https://www.skintherapyletter.com/dermatology/mycophenolate-mofetil/
- Mycophenolate Mofetil Patient Info — British Association of Dermatologists. 2017-09. https://www.skinhealthinfo.org.uk/wp-content/uploads/2018/11/Mycophenolate-Mofetil-Update-September-2017-Lay-review-August-20173.pdf
- Mycophenolate Mofetil (CellCept) — Rixis Dermatology. Accessed 2026. https://www.rixisdermatology.com/mycophenolate-mofetil
- Using Mycophenolate Mofetil to Treat Skin Conditions — UW Health. 2011. https://healthonline.washington.edu/sites/default/files/record_pdfs/Using_Mycophenolate_Mofetil_Skin_4_11.pdf
Similar Articles
Read full bio of Sneha Tete
